34 results about "Viral therapy" patented technology

The present invention relates to compounds according to the general formula:wherein B isorand the remaining variables are defined in the specification, and compositions comprising the compounds. The compounds are useful as anti-viral agents in viral therapy.

Embodiments enables a wearable phototherapy apparatus that produces beneficial effects to a human body such as anti-viral effects, activation of stem cells, improvement in strength, improvement in stamina, pain relief via a non-transdermal container. May include an optional transdermal container that releases or increases copper peptide GHK-Cu in a subject's body. The non-transdermal apparatus reflects or emits specific wavelengths of light to elevate levels of the copper peptide GHK-Cu in the body. The non-transdermal apparatus includes one or more materials that prevent the Left-Handed molecule from direct contact with the body while the enclosure is coupled to the body and prevents the Left-Handed molecules from entering the body. Embodiments may include or be used with any bioavailable form of copper, e.g., such as copper glycinate as an anti-viral therapy and may include an anti-inflammatory or both.

A composition for expressing a polypeptide within a target organ, the composition comprising a delivery particle, and at least a first mRNA sequence complexed with, encapsulated by, or otherwise associated with the delivery particle. The mRNA sequence comprises a coding sequence which codes for the polypeptide, at least a first untranslated region (UTR) sequence, and at least one micro-RNA (miRNA)binding site sequence, wherein the miRNA binding site sequence is located within, immediately 5' to, or immediately 3' to, the first UTR sequence. The miRNA binding site sequence is selected so as toprovide for differential expression of the coding sequence between first and second cell types comprised within the target organ. The composition may be used in combination with or to supplement other therapeutic approaches, including chemotherapy, oncolytic viral therapy, and cellular therapies. Methods for making and using the composition are provided, particularly in treatment of disease, suchas cancer of the liver, brain, lung, breast and pancreas.

The invention relates to methods for generating cell-type specific expression cassettes and reporter vectors, as well as nucleic acid constructs that can be generated by such methods. The cell-type specific expression cassettes and reporter vectors are characterized synthetic cis-regulatory DNA, also termed synthetic locus regions (sLCRs). sLCRs allow for a cell-type specific expression of reporter or effector genes. The invention further relates to various uses of the reporter vectors, including the determination of a property of a cell, preferably a cell type, state or fate transition, in gene and viral therapy, drug discovery or validation.

The present invention provides a recombinant influenza virus vector comprising an NS gene encoding a truncated NS1 protein of at least 73 and up to 122 amino acids of the N-terminus of the respective wild type NS 1 protein, wherein said vector replicates in IFN-sensitive tumor cells and does not replicate in normal, non-tumor cells, and expresses a heterologous immunostimulatory polypetide. The invention further provides a pharmaceutical composition containing said influenza virus vector, its use for the treatment of cancer patients and methods for producing said influenza virus vaccine.